Mohamad Te Navab

US Patent:

6664230, Dec 16, 2003

Filed:

Aug 24, 2000

Appl. No.:

09/645454

Inventors:

Alan M. Fogelman - Beverly Hills CA
Gattadahalli M. Anantharamaiah - Birmingham AL
Mohamad Navab - Los Angeles CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 3808

US Classification:

514 13, 514 12, 514 14, 514 15, 530324, 530325, 530326, 530327, 530328, 530345

Abstract:

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route.

US Patent:

6869568, Mar 22, 2005

Filed:

Jun 5, 2003

Appl. No.:

10/455243

Inventors:

Alan M. Fogelman - Beverly Hills CA, US
Mohamad Navab - Los Angeles CA, US
Susan Hama - Torrance CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N021/77
G01N033/92

US Classification:

422 56, 422 55, 436 63, 436 71, 436169, 436170

Abstract:

This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e. g. lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.

US Patent:

6930085, Aug 16, 2005

Filed:

Apr 5, 2002

Appl. No.:

10/120508

Inventors:

Alan M. Fogelman - Beverly Hills CA, US
Mohamad Navab - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K038/08
A61K038/10
A61K038/16
C07K007/06
C07K007/08

US Classification:

514 2, 514 7, 514 12, 514 13, 514 14, 514 15, 530300, 530324, 530325, 530326, 530327, 530328, 530345

Abstract:

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.

US Patent:

6933279, Aug 23, 2005

Filed:

Jun 29, 2001

Appl. No.:

09/896841

Inventors:

Alan M. Fogelman - Beverly Hills CA, US
Gattadahalli M. Anantharamaiah - Birmingham AL, US
Mohamad Navab - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K038/10
A61K038/16
C07K007/08
C07K014/00

US Classification:

514 13, 514 12, 530324, 530325, 530326, 530345

Abstract:

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route.

US Patent:

7148197, Dec 12, 2006

Filed:

Aug 26, 2003

Appl. No.:

10/649378

Inventors:

Alan M Fogelman - Beverly Hills CA, US
Gattadahalli M Anantharamaiah - Birmingham CA, US
Mohamad Navab - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA
The University of Alabama Research Foundation - Birmingham AL

International Classification:

A61K 38/07
C07K 5/10

US Classification:

514 18, 530330

Abstract:

This invention provides novel peptides for the treatment of atherosclerosis. In certain embodiments the peptide is X-X-X-Xwhere Xand Xare independently selected from the group consisting of alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), proline (Pro), phenylalanine (Phe), tryptophan (Trp), methionine (Met), serine (Ser) bearing a hydrophobic protecting group, beta-naphthyl alanine, alpha-naphthyl alanine, norleucine, cyclohexylalanine, threonine (Thr) bearing a hydrophobic protecting group, tyrosine (Tyr) bearing a hydrophobic protecting group, lysine (Lys) bearing a hydrophobic protecting group, arginine (Arg) bearing a hydrophobic protecting group, ornithine (Orn) bearing a hydrophobic protecting group, aspartic acid (Asp) bearing a hydrophobic protecting group, cysteine (Cys) bearing a hydrophobic protecting group, and glutamic acid (Glu) bearing a hydrophobic protecting group; Xand Xare independently selected from the group consisting of Asp, Arg, and Glu; and the peptide converts pro-inflammatory HDL to anti-inflammatory HDL or makes anti-inflammatory HDL more anti-inflammatory.

US Patent:

7166578, Jan 23, 2007

Filed:

Oct 16, 2002

Appl. No.:

10/273386

Inventors:

Alan M Fogelman - Beverly Hills CA, US
Gattadahalli M Anantharamaiah - Birmingham CA, US
Mohamad Navab - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA
The University of Alabama Research Foundation - Birmingham AL

International Classification:

A61K 38/10
A61K 38/16

US Classification:

514 13, 514 12

Abstract:

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages. In certain embodiments, the peptides range in length from about 10 up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent.

US Patent:

7199102, Apr 3, 2007

Filed:

Apr 25, 2003

Appl. No.:

10/423830

Inventors:

Alan M Fogelman - Beverly Hills CA, US
Gattadahalli M Anantharamaiah - Birmingham CA, US
Mohamad Navab - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 38/10
A61K 38/16
C07K 7/08
C07K 14/00

US Classification:

514 13, 514 12, 530324, 530326

Abstract:

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides typically range in length up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

US Patent:

7250304, Jul 31, 2007

Filed:

Feb 7, 2005

Appl. No.:

11/053123

Inventors:

Alan M Fogelman - Beverly Hills CA, US
Mohamad Navab - Los Angeles CA, US
Susan Hama - Torrance CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

G01N 33/92

US Classification:

436 71, 436161, 436164, 436172, 436173, 422 70, 422 8205, 422 8208, 435 11

Abstract:

This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e. g. , lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.